Table 2.
Detailed characteristics of the patients included in the case series.
| Patient | Type of Infection | Aetiology | First Regimen | First Regimen Duration | Dalbavancin Regimen | Dalbavancin Duration | CCI | Prosthetic Removal | TDM | Clinical Success End of Treatment (Total Weeks from Beginning of Antibiotic Therapy) |
Clinical Success Six Months Follow-Up | Follow-Up (Weeks) | Death (Weeks from End of Treatment) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (62 y) | CEDI infection | MSSA | Oxacillin | 3 weeks | 1500 mg + 1500 mg | 6 weeks | 4 | Yes | Yes | Yes (9 w) | Yes | 65 w | No |
| 2 (80 y) | Periprosthetic aortic abscess at the mitro-aortic junction + thoracic aortic endoprosthesis infection in myelofibrosis (PVE + PVGI) | Unknown | Doxycycline + rifampin, then daptomycin + ceftriaxone | 3 weeks | 1500 mg + 1500 mg then 1000 mg every 14 d | 13 weeks | 9 | No | No | No (16 w) | No | - | Yes (47 w) |
| 3 (45 y) | Periprosthetic aortic abscess (PVE) | Gemella morbillorum | Vancomycin + gentamycin then daptomycin + gentamycin | 3 weeks | 1500 mg + 1500 mg | 6 weeks | 1 | Yes | No | Yes (9 w) | Yes | 144 w | No |
| 4 (80 y) | Prosthetic aortic endocarditis (PVE) | Enterococcus faecalis | Ceftriaxone + ampicillin then daptomycin + ceftriaxone |
4 weeks | 1500 mg + 1500 mg | 6 weeks | 7 | No | No | Yes (10 w) | Yes | 46 w | Yes (46 w) |
| 5 (56 y) | Aortic endoprosthesis infection (PVGI) | Staphylococcus capitis | Daptomycin + ceftriaxone then oxacillin + rifampin |
3 weeks | 1500 mg + 1500 mg then 1000 mg every 14 d | 17 weeks | 3 | Yes | Yes | Yes (20 w) | Yes | 78 w | No |
| 6 (50 y) | CEDI infection with peripheric embolization and spondylodiscitis | MSSA | Daptomycin + cefazolin then daptomycin then teicoplanin |
4 weeks | 1500 mg + 1500 mg then 1000 mg every 14 d, then according TDM | 49 weeks | 4 | Partial | Yes | No (53 w) | No | - | No |
| 7 (80 y) | Prosthetic aortic endocarditis with peripheric embolization with stroke, splenic and intestinal infarctions (PVE) | MSSA | Cefazolin + rifampin | 4 weeks | 1500 mg + 1500 mg, missing data concerning timing additional doses | 8 weeks | 10 | No | No | No (12 w) | No | - | Yes (21 w) |
| 8 (69 y) | Prosthetic aortic endocarditis (PVE) | Streptococcus mitis/oralis | Daptomycin + ceftriaxone | 1 week | 1500 mg + 1500 mg | 6 weeks | 7 | No | No | Yes (7 w) | Yes | 91 w | Yes (91 w) |
| 9 (81 y) | Prosthetic aortic endocarditis and CEDI infection, spondylodiscitis (PVE + CEDI infection) | Staphylococcus lugdunensis | Oxacillin | 1 weeks | 1500 mg + 1500 mg then according TDM | 24 weeks | 8 | No | Yes | Yes (25 w) | Yes | 44 w | Yes (44 w) |
| 10 (51 y) | Prosthetic aortic endocarditis with splenic abscess and spondylodiscitis + ascending aorta endoprosthesis infection (PVE + PVGI) | Streptococcus sanguinis | Daptomycin + ceftriaxone then daptomycin + ampicillin |
4 weeks | 1500 mg + 1500 mg then 1000 mg every 14d | 14 weeks | 0 | No | Yes | Yes (18 w) | Yes | 83 w | No |
| 11 (70 y) | Axillo-femoral bypass infection (PVGI) | MRSA | Vancomycin | 3 weeks | 1500 mg + 1500 mg then according TDM | 26 weeks | 5 | No | Yes | Yes (29 w) | Yes | 23 w | No |
| 12 (56 y) | Aortic endoprosthesis infection (PVGI) |
MSSA + Acinetobacter baumanniii | Oxacillin + rifampin then association with cotrimoxazole |
3 weeks | 1500 mg + 1500 mg then according TDM | 11 weeks | 3 | Yes | Yes | Yes (14 w) | Yes | 38 w | No |
| 13 (78 y) | Prosthetic aortic endocarditis + ascending aorta endoprosthesis infection (PVE + PVGI) | Sreptococcus pasteurianus | Cefotaxime then ampicillin | 6 weeks | 1500 mg + 1500 mg then according TDM | 41 weeks | 3 | No | Yes | Yes (47 w) | - | - | No |
| 14 (72 y) | Endovascular graft infection (PVGI) | C. striatum | Teicoplanin then linezolid | 5 weeks | 1500 mg + 1500 mg then according TDM | ongoing | 6 | Partial | Yes | - | - | - | No |
Abbreviations: CEDI, cardiac implantable electronic devices infections; PVE, Prosthetic valve endocarditis; PVGI, Prosthetic vascular graft infection; MSSA, Methicillin-sensitive Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus; CCI, Charlson Comorbidity Index; TDM, therapeutic drug monitoring.